FDA updates GMPs
This article was originally published in The Tan Sheet
Executive SummaryFDA revises its good manufacturing practice regulations for finished pharmaceuticals to clarify some of the requirements and harmonize them with other FDA standards and international GMPs as part of its first phase of its incremental approach to modifying the GMPs for finished drugs, according to a final rule published in the Sept. 8 Federal Register. Specifically, the rule revises requirements related to aseptic processing, verification of performance of operations by a second individual and use of asbestos filters. The rule applies to all finished pharmaceuticals, both under new drug applications and OTC monographs. "We are pleased to see the agency updating GMPs and feel it is important they continue to do so," commented Elizabeth Funderburk, Consumer Products Healthcare Association director of communications
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.